UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  June 22, 2005

 

EPIX Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

 

 

000-21863

 

04-3030815

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

161 First Street, Cambridge, Massachusetts 02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

 

(617) 250-6000

(Registrant’s Telephone Number, Including Area Code)

 

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

(a), (c) and (d) Not applicable.

 

(b)  On June 22, 2005, Dr. Stanley T. Crooke, a Director of EPIX Pharmaceuticals, Inc., delivered to the Company a notice of his retirement, effective immediately, from the Board of Directors.  A copy of that notice is attached hereto as Exhibit 99.1.

 

Item 9.01.   Financial Statements and Exhibits.

 

(c) The following exhibits are furnished with this report:

 

Exhibit Number

 

Description

99.1

 

Notice of Retirement, dated June 22, 2005.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
EPIX Pharmaceuticals, Inc.

 

(Registrant)

 

 

 

 

Date: June 24, 2005

/s/ Peyton J. Marshall

 

 

Peyton J. Marshall

 

Senior Vice-President,

 

Finance and Administration,

 

Chief Financial Officer

 

3